Corbus Historical Balance Sheet

CRBP Stock  USD 17.82  0.18  1.02%   
Trend analysis of Corbus Pharmaceuticals Holding balance sheet accounts such as Total Assets of 50.5 M, Short and Long Term Debt Total of 11.1 M or Other Current Liab of 9 M provides information on Corbus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Corbus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Corbus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Corbus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corbus Pharmaceuticals is a good buy for the upcoming year.

Corbus Pharmaceuticals Inventory

330,750

  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About Corbus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Corbus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Corbus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Corbus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Corbus currently owns. An asset can also be divided into two categories, current and non-current.

Corbus Pharmaceuticals Balance Sheet Chart

At this time, Corbus Pharmaceuticals' Short Term Debt is relatively stable compared to the past year. As of 12/02/2024, Property Plant And Equipment Net is likely to grow to about 4.6 M, while Other Current Liabilities is likely to drop slightly above 9 M.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Corbus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Corbus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Corbus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Corbus Pharmaceuticals Holding are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Corbus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Corbus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.
Most accounts from Corbus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
At this time, Corbus Pharmaceuticals' Short Term Debt is relatively stable compared to the past year. As of 12/02/2024, Property Plant And Equipment Net is likely to grow to about 4.6 M, while Other Current Liabilities is likely to drop slightly above 9 M.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total26.6M25.1M20.9M11.1M
Total Assets107.7M66.3M28.3M50.5M

Corbus Pharmaceuticals balance sheet Correlations

-0.170.11-0.19-0.16-0.19-0.140.41-0.04-0.34-0.34-0.04-0.16-0.170.08-0.270.03-0.07-0.180.09-0.3-0.31-0.07-0.1-0.080.03
-0.170.770.710.640.840.67-0.44-0.690.520.760.690.980.770.820.660.80.821.00.230.760.180.870.780.790.21
0.110.770.640.670.470.680.07-0.880.310.390.750.730.820.890.460.950.880.750.50.41-0.310.670.770.80.46
-0.190.710.640.950.340.94-0.43-0.630.910.690.820.620.680.60.940.670.930.670.290.590.040.430.950.940.36
-0.160.640.670.950.230.86-0.3-0.740.850.590.860.540.770.510.90.760.920.60.480.460.030.450.880.890.54
-0.190.840.470.340.230.3-0.55-0.270.20.70.250.920.380.650.350.490.440.86-0.20.790.390.810.410.41-0.26
-0.140.670.680.940.860.3-0.31-0.580.80.60.70.580.60.690.860.620.90.620.220.57-0.240.330.950.950.28
0.41-0.440.07-0.43-0.3-0.55-0.31-0.14-0.54-0.89-0.06-0.48-0.06-0.13-0.49-0.01-0.24-0.450.37-0.56-0.64-0.34-0.24-0.230.24
-0.04-0.69-0.88-0.63-0.74-0.27-0.58-0.14-0.39-0.3-0.88-0.59-0.96-0.64-0.52-0.94-0.82-0.67-0.8-0.20.16-0.65-0.72-0.75-0.76
-0.340.520.310.910.850.20.8-0.54-0.390.650.680.420.50.320.930.40.720.480.120.480.250.190.80.780.22
-0.340.760.390.690.590.70.6-0.89-0.30.650.420.760.470.510.680.440.630.77-0.060.690.460.620.580.580.05
-0.040.690.750.820.860.250.7-0.06-0.880.680.420.570.860.590.710.840.880.650.610.330.070.510.830.840.61
-0.160.980.730.620.540.920.58-0.48-0.590.420.760.570.670.820.570.760.750.980.080.80.240.880.690.70.05
-0.170.770.820.680.770.380.6-0.06-0.960.50.470.860.670.60.610.910.830.750.740.340.00.720.720.740.73
0.080.820.890.60.510.650.69-0.13-0.640.320.510.590.820.60.420.770.810.80.110.58-0.240.60.760.780.08
-0.270.660.460.940.90.350.86-0.49-0.520.930.680.710.570.610.420.560.80.620.240.580.170.430.880.860.3
0.030.80.950.670.760.490.62-0.01-0.940.40.440.840.760.910.770.560.880.780.580.39-0.070.750.760.790.54
-0.070.820.880.930.920.440.9-0.24-0.820.720.630.880.750.830.810.80.880.780.420.56-0.10.590.950.970.45
-0.181.00.750.670.60.860.62-0.45-0.670.480.770.650.980.750.80.620.780.780.210.760.210.890.730.750.19
0.090.230.50.290.48-0.20.220.37-0.80.12-0.060.610.080.740.110.240.580.420.21-0.21-0.220.380.30.330.97
-0.30.760.410.590.460.790.57-0.56-0.20.480.690.330.80.340.580.580.390.560.76-0.210.220.590.580.57-0.24
-0.310.18-0.310.040.030.39-0.24-0.640.160.250.460.070.240.0-0.240.17-0.07-0.10.21-0.220.220.29-0.12-0.14-0.18
-0.070.870.670.430.450.810.33-0.34-0.650.190.620.510.880.720.60.430.750.590.890.380.590.290.470.50.31
-0.10.780.770.950.880.410.95-0.24-0.720.80.580.830.690.720.760.880.760.950.730.30.58-0.120.471.00.32
-0.080.790.80.940.890.410.95-0.23-0.750.780.580.840.70.740.780.860.790.970.750.330.57-0.140.51.00.35
0.030.210.460.360.54-0.260.280.24-0.760.220.050.610.050.730.080.30.540.450.190.97-0.24-0.180.310.320.35
Click cells to compare fundamentals

Corbus Pharmaceuticals Account Relationship Matchups

Corbus Pharmaceuticals balance sheet Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding2.1M2.6M4.1M4.2M4.3M2.9M
Total Assets49.1M102.3M107.7M66.3M28.3M50.5M
Short Long Term Debt Total9.4M26.8M26.6M25.1M20.9M11.1M
Other Current Liab22.4M21.8M10.2M6.0M11.1M9.0M
Total Current Liabilities34.9M31.9M17.0M12.6M31.9M16.9M
Total Stockholder Equity6.2M45.3M69.1M33.0M(6.9M)(6.6M)
Net Debt(22.3M)(58.6M)1.6M8.1M7.2M7.5M
Retained Earnings(192.8M)(304.1M)(349.7M)(392.1M)(436.7M)(414.8M)
Accounts Payable11.1M7.4M1.8M2.2M3.2M4.0M
Cash31.7M85.4M25.0M17.0M13.9M13.2M
Cash And Short Term Investments31.7M85.4M97.6M59.2M20.9M19.9M
Common Stock Total Equity5.6K5.7K6.5K9.9K11.4K11.9K
Liabilities And Stockholders Equity49.1M102.3M107.7M66.3M28.3M50.5M
Non Current Liabilities Total8.1M25.1M21.6M20.7M3.3M3.1M
Other Current Assets6.4M4.1M2.6M984.1K2.6M2.4M
Other Stockholder Equity199.0M349.4M418.9M425.2M429.8M216.4M
Total Liab43.0M57.0M38.6M33.3M35.2M25.1M
Total Current Assets38.2M92.1M100.2M60.2M23.5M46.1M
Short Term Debt1.3M2.7M5.0M4.4M17.6M18.5M
Common Stock6.5K9.9K12.5K417.0442.0419.9
Net Tangible Assets6.2M45.3M69.1M33.0M37.9M32.1M
Property Plant And Equipment Net10.9M9.3M7.0M5.5M4.0M4.6M
Non Current Assets Total11.0M10.2M7.5M6.1M4.7M4.9M
Non Currrent Assets Other85.0K234.0K46.4K155.3K690.2K724.7K
Retained Earnings Total Equity(65.7M)(121.4M)(192.8M)(304.1M)(273.7M)(260.0M)
Capital Surpluse123.5M148.9M199.0M349.4M401.8M421.9M
Property Plant And Equipment Gross10.9M9.3M7.0M5.5M7.6M5.0M
Short Long Term Debt752.7K710.2K3.9M3.1M16.2M17.0M
Accumulated Other Comprehensive Income(666.6K)(1.4M)(62.4K)(126.1K)(1.6K)(1.6K)
Property Plant Equipment5.1M9.3M7.0M5.5M6.3M3.9M

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

  0.74VALN Valneva SE ADRPairCorr

Moving against Corbus Stock

  0.64VERA Vera TherapeuticsPairCorr
  0.59DRUG Bright Minds Biosciences TrendingPairCorr
  0.56VCYT VeracytePairCorr
  0.51SABSW SAB BiotherapeuticsPairCorr
  0.34DMAC DiaMedica Therapeutics TrendingPairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Corbus Stock Analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.